Guggenheim Covers InflaRx (IFRX); ADVANCED DRAINAGE SYSTEMS (WMS) Has 1.54 Sentiment – The Financial Examiner

The broker Guggenheim has began coverage on InflaRx (NASDAQ:IFRX)‘s stock, rating it Buy. This was sent to investors in a research note on 22 February.

ADVANCED DRAINAGE SYSTEMS (WMS) investors sentiment decreased to 1.54 in Q3 2018. It’s down -0.24, from 1.78 in 2018Q2. The ratio has dropped, as 74 active investment managers increased and started new equity positions, while 48 reduced and sold their stakes in ADVANCED DRAINAGE SYSTEMS. The active investment managers in our database now have: 41.75 million shares, down from 43.63 million shares in 2018Q2. Also, the number of active investment managers holding ADVANCED DRAINAGE SYSTEMS in top ten equity positions was flat from 3 to 3 for the same number . Sold All: 8 Reduced: 40 Increased: 33 New Position: 41.

Advanced Drainage Systems, Inc. designs, makes, and markets thermoplastic corrugated pipes and related water management products for non-residential, residential, agriculture, and infrastructure applications in the United States and internationally. The company has market cap of $1.49 billion. The firm provides single, double, and triple wall corrugated polypropylene and polyethylene pipes; and allied products comprising storm retention/detention and septic chambers, polyvinyl chloride drainage structures, fittings, and water quality filters and separators. It has a 23.26 P/E ratio. It also purchases and distributes construction fabrics, as well as other geosynthetic products for soil stabilization, reinforcement, filtration, separation, erosion control, and sub-surface drainage.

Berkshire Partners Llc holds 19.23% of its portfolio in Advanced Drainage Systems, Inc. for 6.76 million shares. Ack Asset Management Llc owns 1.12 million shares or 9.51% of their US portfolio. Moreover, Stockbridge Partners Llc has 4.6% invested in the company for 3.76 million shares. The Connecticut-based White Elm Capital Llc has invested 1.25% in the stock. Par Capital Management Inc, a Massachusetts-based fund reported 2.74 million shares.

More important recent Advanced Drainage Systems, Inc. (NYSE:WMS) news were published by: Seekingalpha.com which released: “Advanced Drainage Systems (WMS) CEO Scott Barbour on Q3 2019 Results – Earnings Call Transcript – Seeking Alpha” on February 08, 2019, also Zacks.com published article titled: “Advanced Drainage Systems (WMS) Reports Next Week: Wall Street Expects Earnings Growth – Zacks.com”, Investorideas.com published: “Investor Ideas Adds New #Homebuilder, Mining, #eSports and #AI Stocks: ($CSWI, $MYRG, $JCTCF, $WMS, $ALLE, $CBPX, $ROCK, $PGTI, $USG) – InvestorIdeas.com” on February 15, 2019. More interesting news about Advanced Drainage Systems, Inc. (NYSE:WMS) was released by: Seekingalpha.com and their article: “Advanced Drainage Systems (WMS) CEO Scott Barbour on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” with publication date: August 12, 2018.

The stock increased 0.27% or $0.07 during the last trading session, reaching $26.01. About 68,024 shares traded. Advanced Drainage Systems, Inc. (WMS) has risen 8.52% since February 22, 2018 and is uptrending. It has outperformed by 8.52% the S&P500. Some Historical WMS News: 06/03/2018 Advanced Drainage Systems Launches “ADS Installation Guides” Mobile App; 24/04/2018 – New Research: Key Drivers of Growth for Cross Country Healthcare, Tribune Media, W.P. Carey, Advanced Drainage, Ambac Financial; 06/03/2018 – Advanced Drainage Systems Launches “ADS Installation Guides” Mobile App; 29/05/2018 – Correct: Advanced Drainage Systems Sees FY19 Adjusted EBITDA $220M-$240M; 21/03/2018 – ADVANCED DRAINAGE EVP, CO-COO FUSSNER TO RETIRE; 29/05/2018 – Advanced Drainage Systems Narrows 4Q Loss; 30/05/2018 – Advanced Drainage Systems, Inc. Appoints New Directors; 29/05/2018 – Advanced Drainage Systems 4Q Adjusted EBITDA $220M-$240M; 07/03/2018 – Norges Bank Exits Position in Advanced Drainage; 29/05/2018 – ADVANCED DRAINAGE 4Q LOSS/SHR 11C

Analysts await InflaRx N.V. (NASDAQ:IFRX) to report earnings on April, 4. After $-0.31 actual EPS reported by InflaRx N.V. for the previous quarter, Wall Street now forecasts 32.26% negative EPS growth.

The stock increased 1.13% or $0.36 during the last trading session, reaching $32.33. About 591,547 shares traded or 692.69% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 63.49% since February 22, 2018 and is uptrending. It has outperformed by 63.49% the S&P500. Some Historical IFRX News: 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6

InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. The company has market cap of $829.66 million. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The firm is involved in developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases.

More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Globenewswire.com which released: “InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa – GlobeNewswire” on February 06, 2019, also Nasdaq.com with their article: “Kirkland Lake Gold Reports Record Earnings and Cash Flow in Q4 and Full-Year 2018 – Nasdaq” published on February 21, 2019, Nasdaq.com published: “Teranga Gold Reports Q4 and Full Year 2018 Financial and Operating Results – Nasdaq” on February 22, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “Maersk shares plummet on bleak outlook as trade war looms – Nasdaq” published on February 21, 2019 as well as Nasdaq.com‘s news article titled: “PROREIT Named Among Top Performers on TSX-V – Nasdaq” with publication date: February 21, 2019.

InflaRx N.V. (NASDAQ:IFRX) Ratings Chart


Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *